Cognitive and PET studies of postmenopausal women

Chakravorty, Sayan; Lockwood, A.; Halbreich, Uriel

doi:10.1016/0006-3223(96)84430-1

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, it has been shown that BDNF has antidepressant effects in two behavioral models of depression in rats [145] and that electroconvulsive therapy as well as chronic, but not acute, administration of several different antidepressant drugs increase the expression of BDNF in frontal cortex and the expression of BDNF and its trkB receptor in the In women of reproductive age, blood MAO, 5-HT levels, platelet 5-HT 2A receptor binding, 5-HT uptake, and 3 H-imipramine binding all fluctuate with the phase of the menstrual cycle and levels of ovarian hormones [102]. Chakravorty and Halbreich [124] have recently reviewed the influence of estrogen on the activity of MAO, an oxidase involved dominantly in the metabolism of hippocampus [146,147]. The enhanced induction and prolonged expression of BDNF in response to chronic electroconvulsive and antidepressant drug treatments could promote neuronal survival and protect 5-HT and norepinephrine neurons from neurotoxic damage [148].…”

Section: Depressionmentioning

confidence: 97%

Drugs with Estrogen-like Potency and Brain Activity Potential Therapeutic Application for the CNS

Cyr¹,

Calon²,

Morissette³

et al. 2000

CPD

102

View full text Add to dashboard Cite

Numerous reports, ranging from molecular investigations to clinical studies, demonstrate the potency of estrogens to modulate brain function and their implications in schizophrenia and depression. Alterations of dopaminergic, cholinergic, GABAergic, glutamatergic and serotonergic neurotransmission through estrogen-mediated mechanisms have been consistently established. Moreover, studies using in vivo and in vitro models as well as epidemiological data suggest that estrogens provide neuroprotection of central nervous system (CNS) cells implicated in the etiology of neurodegenerative disorders such as Alzheimer s (AD) and Parkinson s (PD) diseases. Numerous genomic or non-genomic mechanisms of actions of estrogens in the brain have been documented implicating classical nuclear estrogen receptors as well as possible estrogen membrane receptors, antioxidant activity of steroids, their effect on fluidity as well as on antiapoptotic proteins and growth factors. Selective estrogen receptor modulators (SERMs) have estrogenic and/or antiestrogenic activity depending on the target tissue. Hence, SERMs have the same beneficial effect as estrogen in skeleton and cardiovascular systems but act as antagonists in breast and uterus. The finding of beneficial side effects of SERMs in the CNS might improve their risk-benefit ratio in traditional indications. In this review, we will survey schizophrenia and depression as examples of mental diseases and AD and PD as neurodegenerative diseases. We will review brain effects of estrogens, steroids possibly acting as pro-drugs of estrogens such as testosterone and dehydroepiandrosterone (DHEA) and present novel findings with SERMs. Drugs with estrogen activity in the brain may have therapeutic potential either by modulating brain neurotransmitter transmission or through neuroprotective activity.

show abstract